{"id":987443,"date":"2026-07-30T12:25:50","date_gmt":"2026-07-30T16:25:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/"},"modified":"2026-07-30T12:25:50","modified_gmt":"2026-07-30T16:25:50","slug":"capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/","title":{"rendered":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }\n.bwalignc { text-align: center; list-style-position:inside }\n.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law<\/p>\n<p>BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.<\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Leading securities law firm <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=Bleichmar+Fonti+%26+Auld+LLP&amp;index=1&amp;md5=22dc8a3c433fef78e8f11e50af4b8fa2\"><b>Bleichmar Fonti &amp; Auld LLP<\/b><\/a> announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop.<\/p>\n<p>If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=2&amp;md5=454f36e07a9ff61581e37b265dbe7a02\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><b>.<\/b><\/p>\n<p><b>Key Details of the Capricor Therapeutics ($CAPR) Class Action Investigation:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Investigation Overview: <\/b>Securities fraud relating to Capricor\u2019s statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.<\/li>\n<li><b>Stock Decline: <\/b>July 27, 2026 \u2013 64.5% Stock Drop<\/li>\n<li><b>Action: <\/b>Contact <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=BFA+Law&amp;index=3&amp;md5=f44d8dd46e59b57753d33a6bf2dd8d00\">BFA Law<\/a> to discuss your rights<\/li>\n<\/ul>\n<p><b>Why is Capricor Being Investigated for Securities Fraud?<\/b><\/p>\n<p>Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy.<\/p>\n<p>BFA is investigating whether Capricor misled investors about Deramiocel\u2019s clinical data, including the company\u2019s statements concerning positive topline results and its regulatory path with the FDA.<\/p>\n<p><b>Why did Capricor\u2019s Stock Drop?<\/b><\/p>\n<p>On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor\u2019s statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded.<\/p>\n<p>This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day.<\/p>\n<p><b>Click here for more information: <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=4&amp;md5=8d389b90e10e816115a715e62c651659\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><b>.<\/b><\/p>\n<p><b>What Can You Do?<\/b><\/p>\n<p>If you invested in Capricor Therapeutics securities, you may have legal options and are encouraged to submit your information to the firm.<\/p>\n<p>All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n<p><b>Submit your information by visiting:<\/b><\/p>\n<p class=\"bwalignc\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=5&amp;md5=cb7b86c71cb18ae5cae1576e5dd5be9b\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><\/p>\n<p>Or contact:<\/p>\n<p>Adam McCall<br \/><a rel=\"nofollow\" href=\"mailto:adam@bfalaw.com\">adam@bfalaw.com<\/a><br \/>212.789.3619<\/p>\n<p><b>Why Bleichmar Fonti &amp; Auld LLP?<\/b><\/p>\n<p>BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by <i>Chambers USA<\/i>, <i>The Legal 500<\/i>, and <i>ISS SCAS<\/i>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the <i>National Law Journal<\/i>, \u201cLitigation Stars\u201d by <i>Benchmark Litigation<\/i>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by <i>Lawdragon<\/i>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by <i>Law360<\/i> and \u201cSuperLawyers\u201d by Thomson Reuters.<\/p>\n<p>Most recently, <i>The Legal 500 <\/i>awarded BFA the most client satisfaction accolades of any plaintiff\u2019s securities litigation law firm, with clients noting: \u201c[t]here is no better service provider in the practice area,\u201d \u201c[t]he interest of the client is always front and center,\u201d and \u201c[t]here isn\u2019t a better firm in this space.\u201d One testimonial described the firm as \u201cnimble and entrepreneurial,\u201d with a \u201crelentless focus on adding value for clients.\u201d<\/p>\n<p>Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n<p>For more information about BFA and its attorneys, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com&amp;index=6&amp;md5=7dfb3c90cddb9bc0203c1372c35af8da\">https:\/\/www.bfalaw.com<\/a>.<\/p>\n<p class=\"bwalignc\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;esheet=54580304&amp;newsitemid=20260730338978&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fcapricor-class-action-lawsuit&amp;index=7&amp;md5=317711224a43593fc2e0de2886990b94\"><b>https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit<\/b><\/a><\/p>\n<p><i>Attorney advertising. Past results do not guarantee future outcomes.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260730338978\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260730338978\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Adam McCall<br \/><a rel=\"nofollow\" href=\"mailto:adam@bfalaw.com\">adam@bfalaw.com<\/a><br \/>212.789.3619<\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260730338978\/en\/2864420\/3\/BFA_Law_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application. NEW YORK&#8211;(BUSINESS WIRE)&#8211;Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop. If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit. Key Details of the Capricor Therapeutics ($CAPR) Class Action Investigation: Investigation Overview: Securities fraud relating to Capricor\u2019s statements concerning Deramiocel and the integrity of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-987443","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application. NEW YORK&#8211;(BUSINESS WIRE)&#8211;Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop. If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit. Key Details of the Capricor Therapeutics ($CAPR) Class Action Investigation: Investigation Overview: Securities fraud relating to Capricor\u2019s statements concerning Deramiocel and the integrity of &hellip; Continue reading &quot;CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T16:25:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law\",\"datePublished\":\"2026-07-30T16:25:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/\"},\"wordCount\":660,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/\",\"name\":\"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-30T16:25:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/","og_locale":"en_US","og_type":"article","og_title":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk","og_description":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application. NEW YORK&#8211;(BUSINESS WIRE)&#8211;Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop. If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/capricor-class-action-lawsuit. Key Details of the Capricor Therapeutics ($CAPR) Class Action Investigation: Investigation Overview: Securities fraud relating to Capricor\u2019s statements concerning Deramiocel and the integrity of &hellip; Continue reading \"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-30T16:25:50+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law","datePublished":"2026-07-30T16:25:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/"},"wordCount":660,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/","name":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-30T16:25:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260730338978r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-over-64-after-fda-briefing-documents-raise-concerns-triggering-securities-fraud-investigation-by-bfa-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=987443"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987443\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=987443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=987443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=987443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}